JP2020520370A5 - - Google Patents

Download PDF

Info

Publication number
JP2020520370A5
JP2020520370A5 JP2019563581A JP2019563581A JP2020520370A5 JP 2020520370 A5 JP2020520370 A5 JP 2020520370A5 JP 2019563581 A JP2019563581 A JP 2019563581A JP 2019563581 A JP2019563581 A JP 2019563581A JP 2020520370 A5 JP2020520370 A5 JP 2020520370A5
Authority
JP
Japan
Prior art keywords
amino acid
antibody
acid sequence
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019563581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520370A (ja
JP7171617B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/062473 external-priority patent/WO2018210793A2/en
Publication of JP2020520370A publication Critical patent/JP2020520370A/ja
Publication of JP2020520370A5 publication Critical patent/JP2020520370A5/ja
Application granted granted Critical
Publication of JP7171617B2 publication Critical patent/JP7171617B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019563581A 2017-05-16 2018-05-15 抗SIRPα抗体 Active JP7171617B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17171285 2017-05-16
EP17171285.4 2017-05-16
PCT/EP2018/062473 WO2018210793A2 (en) 2017-05-16 2018-05-15 ANTI-SIRPα ANTIBODIES

Publications (3)

Publication Number Publication Date
JP2020520370A JP2020520370A (ja) 2020-07-09
JP2020520370A5 true JP2020520370A5 (https=) 2021-07-26
JP7171617B2 JP7171617B2 (ja) 2022-11-15

Family

ID=58714966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563581A Active JP7171617B2 (ja) 2017-05-16 2018-05-15 抗SIRPα抗体

Country Status (23)

Country Link
US (2) US11274159B2 (https=)
EP (2) EP3625259B1 (https=)
JP (1) JP7171617B2 (https=)
KR (1) KR102714600B1 (https=)
CN (2) CN118271443A (https=)
AR (1) AR111630A1 (https=)
AU (1) AU2018268304B2 (https=)
BR (1) BR112019023754A2 (https=)
CA (1) CA3063622A1 (https=)
CL (1) CL2019003266A1 (https=)
DK (1) DK3625259T3 (https=)
ES (1) ES2981193T3 (https=)
FI (1) FI3625259T3 (https=)
HR (1) HRP20240924T1 (https=)
HU (1) HUE067040T2 (https=)
LT (1) LT3625259T (https=)
MX (1) MX2019013749A (https=)
MY (1) MY199247A (https=)
PL (1) PL3625259T3 (https=)
PT (1) PT3625259T (https=)
RU (1) RU2771174C2 (https=)
TW (1) TWI710574B (https=)
WO (2) WO2018210793A2 (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66062B1 (sr) 2016-04-14 2024-11-29 Ose Immunotherapeutics Nova anti-sirpa antitela i njihove terapijske primene
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
CN118267470A (zh) * 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
MX2020009774A (es) 2018-03-21 2020-10-08 Alx Oncology Inc Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
EP3802602A1 (en) 2018-05-25 2021-04-14 Alector LLC Anti-sirpa antibodies and methods of use thereof
CN112384532B (zh) * 2018-06-29 2025-01-10 艾利妥 抗SIRP-β1抗体及其使用方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
CA3118966A1 (en) * 2018-11-15 2020-05-22 Byondis B.V. Humanized anti-sirpa antibodies
CN114206912B (zh) 2019-06-07 2025-02-11 Alx肿瘤生物技术公司 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
CN114555123B (zh) 2019-10-18 2024-04-02 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
KR20220091576A (ko) 2019-10-31 2022-06-30 포티 세븐, 인코포레이티드 혈액암의 항-cd47 및 항-cd20 기반 치료
AU2020394204A1 (en) 2019-11-27 2022-06-02 ALX Oncology Inc. Combination therapies for treating cancer
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
JP7437815B2 (ja) 2019-12-24 2024-02-26 ラノバ メディシンズ リミテッド 抗SIRPαモノクローナル抗体およびその使用
KR20260017503A (ko) 2020-02-14 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
WO2021226591A1 (en) * 2020-05-08 2021-11-11 Electra Therapeutics, Inc. Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
US12343377B2 (en) 2020-06-01 2025-07-01 ALX Oncology Inc. Combination therapies comprising a hypomethylation agent for treating cancer
CN114560940B (zh) * 2020-11-27 2023-07-14 缔码生物科技(武汉)有限公司 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用
JP7663265B2 (ja) * 2020-11-30 2025-04-16 クレ バイオテクノロジ (シャンハイ) カンパニー リミテッド 抗SIRPα抗体またはその抗原結合断片および適用
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CN112574310B (zh) * 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途
CN112979782B (zh) * 2021-03-08 2023-07-18 深圳市乐土生物医药有限公司 一种多肽及其用途
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用FLT3L—Fc融合蛋白之方法
BR112023025194A2 (pt) * 2021-06-04 2024-02-27 Boehringer Ingelheim Int Anticorpos anti-sirp-alfa
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023020459A1 (zh) * 2021-08-17 2023-02-23 杭州九源基因工程有限公司 靶向SIRPα的单克隆抗体及其用途
AU2022337223A1 (en) * 2021-09-03 2024-04-11 Zymeworks Bc Inc. Fc variant with high thermal stability and attenuated effector function
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
EP4422756A1 (en) 2021-10-29 2024-09-04 Gilead Sciences, Inc. Cd73 compounds
EP4452415B1 (en) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
JP2025523369A (ja) 2022-06-01 2025-07-23 エーエルエックス オンコロジー インコーポレイテッド 尿路上皮癌腫を治療するための併用療法
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN120882725A (zh) 2023-04-11 2025-10-31 吉利德科学公司 Kras调节化合物
WO2024220895A1 (en) * 2023-04-20 2024-10-24 Twist Bioscience Corporation Antibodies and variant nucleic acid libraries for sirp-alpha
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN116715774B (zh) * 2023-05-12 2023-11-24 武汉爱博泰克生物科技有限公司 针对人axl的兔单克隆抗体及其制备方法和应用
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN118344476B (zh) * 2024-05-16 2024-11-15 武汉爱博泰克生物科技有限公司 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN118620078B (zh) * 2024-07-09 2024-11-19 武汉爱博泰克生物科技有限公司 抗人cd45ra蛋白的抗体、抗体偶联物及其应用
WO2026039365A1 (en) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Kras modulating compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU1701001A (en) 1999-11-30 2001-06-12 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibodies against signal regulator proteins
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
RU2597831C2 (ru) * 2011-01-19 2016-09-20 Кантаргия Аб Анти-il1rap антитела и их применение при лечении людей
WO2013056352A1 (en) * 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
WO2013150043A1 (en) * 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
EP3795215A1 (en) * 2012-05-30 2021-03-24 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2015229448B2 (en) * 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
CA2994935A1 (en) * 2015-05-18 2016-11-24 Ab Initio Biotherapeutics, Inc. Sirp polypeptide compositions and methods of use
JP7078533B2 (ja) * 2015-10-21 2022-05-31 オーエスイー イムノセラピューティクス 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗SIRPa化合物
SG11201808465UA (en) 2016-04-14 2018-10-30 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
KR102878970B1 (ko) 2016-08-03 2025-10-30 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴

Similar Documents

Publication Publication Date Title
JP2020520370A5 (https=)
US11718681B2 (en) Anti-SIRP α antibodies
KR102068600B1 (ko) Pdl-1 항체, 그 약학적 조성물 및 그 용도
JP2021524249A5 (https=)
JP2011507932A5 (https=)
JP2018534933A5 (https=)
JP2015509947A5 (https=)
JPWO2019224718A5 (https=)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
US12391764B2 (en) Anti-CD30 and anti-CD3 bispecific antibodies and methods of immunotherapy for CD30+ malignancies
JP2020515577A5 (https=)
Pandey et al. Monoclonal antibodies as therapeutics in human malignancies
JPWO2020099653A5 (https=)
JPWO2020227457A5 (https=)
JPWO2022256559A5 (https=)
JPWO2023098888A5 (https=)
JPWO2021063201A5 (https=)
JPWO2021068841A5 (https=)
JPWO2022101458A5 (https=)
Ward et al. Unconjugated antibodies for cancer therapy: lessons from the clinic
JPWO2020143749A5 (https=)
EP4428158A1 (en) Lung cancer targeting human antibodies and therapeutic uses thereof
HK40104915A (zh) 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法
JPWO2023281313A5 (https=)
JP2026510808A (ja) ヒト抗体を標的とするメラノーマとその治療方法